BackBioNexus Gene Lab Overview

BioNexus Gene Lab Receivables

Track BioNexus Gene Lab's receivables ($120K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$124519.00
↓ 94.08% YoYΔ $-1.98M vs prior year quarter

Peer trimmed avg / median

Loading

BioNexus Gene Lab Receivables History

Loading

BioNexus Gene Lab vs. peers: Receivables Comparison

Loading

BioNexus Gene Lab Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

BioNexus Gene Lab (BGLC) FAQ

As of the most recent data (June 2026), BGLC shows a receivables of $120K. That compares with $2.1M in the prior-year period — down 94.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BGLC's receivables is now $120K (was $2.1M) — a 94.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether BioNexus Gene Lab is outperforming or lagging.

Tracking BGLC's receivables over time shows whether BioNexus Gene Lab is scaling, shrinking, or reshaping that part of the business. The current reading is $120K That compares with $2.1M in the prior-year period — down 94.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has BioNexus Gene Lab's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $120K) with ownership activity and broader fundamentals.